Sudeep Pharma IPO: GMP, price, important dates and more…
- Mani Metto
- 5 days ago
- 2 min read
The Sudeep Pharma IPO is open from November 21 to November 25, 2025, with a price band of ₹563–₹593 per share and a minimum retail investment of ₹14,825 (25 shares per lot). The total offer size is ₹895 crore, split between a ₹95 crore fresh issue and an ₹800 crore Offer for Sale (OFS). Shares are proposed for listing on both BSE and NSE.
IPO Snapshot
Particulars | Details |
Total Issue Size | ₹895 crore |
Fresh Issue | ₹95 crore |
Offer for Sale | ₹800 crore |
Price Band | ₹563–₹593 |
Lot Size | 25 shares |
Minimum Investment | ₹14,825 |
Listing | BSE, NSE |
Issue Dates | Nov 21–Nov 25, 2025 |
Issue Type | Book-building IPO |
Company Overview
Founded in 1989, Sudeep Pharma is a major player in the manufacturing of pharmaceutical excipients, food-grade minerals, and speciality nutrition ingredients. The company’s reach includes:
· 200+ products exported to 100+ countries
· Six manufacturing facilities with a combined 50,000 MT production capacity
· Strong R&D, pilot-scale laboratories, and deep expertise in encapsulation, granulation, and mineral salts
Key Sectors & Clients
Sudeep Pharma primarily serves the pharma, food & nutrition, and speciality ingredients industries, catering to both Indian and global markets across US, Europe, Latin America, APAC, and Africa.
Financial Performance
Period Ended | Revenue (₹ Cr) | Profit After Tax (₹ Cr) |
March 2025 | 511.33 | 138.69 |
March 2024 | 465.38 | 133.15 |
March 2023 | 438.26 | 62.32 |
· Revenue and profits have steadily increased over recent years, with net profit doubling from FY23 to FY24 and maintaining strong margins.
· The IPO values Sudeep Pharma at a Price/Earnings ratio of roughly 48–53 times, reflecting premium positioning versus typical peers.
GMP (Grey Market Premium) Trends
· As of the latest, market sources report an indicative Grey Market Premium (GMP) of ₹115–₹120 per share, implying a potential listing price around ₹710 and estimated listing gains near 20% (subject to demand and market movement).
Peer Comparison
Company | Sales (₹ Cr) | P/E | Net Profit (₹ Cr) |
Fine Organics | 2,220 | 52 | 349 |
Loba Chemie | 1,000+ | NA | NA |
Anupam Rasayan | 3,292 | 66 | 253 |
Sudeep Pharma | 511.33 | 48–53 | 138.69 |
· Sudeep Pharma does not have a direct listed peer in mineral-based excipients, resulting in relatively premium valuations compared to broader chemical peers.
Use of IPO Proceeds
Source | Allocation Details |
Fresh Issue | Capital expenditure for Nandesari Facility I, general corporate purposes (company receives ₹95 crore) |
OFS | Proceeds go entirely to existing shareholders; company does not receive these funds (₹800 crore) |
Additional Highlights
· Strong process innovation with IP-led technologies (encapsulation, granulation, trituration).
· Risks include customer concentration, regulatory compliance, and generic ingredient market pressures.
· Book-running lead managers: IIFL Capital Services, ICICI Securities.
· Registrar: MUFG Intime India.
This IPO stands out due to its niche focus, global reach, and financial momentum, though its higher valuation and sector-specific risks should be considered before investing.
Disclaimer: This content is for educational purposes only; please conduct your own research and consult with a qualified investment advisor before making any investment decisions.
Want to read more?
Subscribe to finsightsbysquareleague.com to keep reading this exclusive post.